Europe PMC

Abstract 


Objective

Intestinal ischemia-reperfusion injury (I/R) is a common syndrome encountered in clinic following intestinal surgery, strangulated hernia, and shock. Hypertonic saline has been shown to prevent inflammatory tissue damages caused by I/R and regulate immunologic disorders in peripheral blood. However, the immunoregulatory effects of hypertonic saline on the small intestine response to intestinal I/R have not been reported.

Materials and methods

To investigate this, we created the intestinal I/R model by clamping the superior mesenteric artery in Sprague-Dawley rats. After 1 hour of ischemia, the vascular clamp was removed, and either normal saline (0.9% NaCl, NS group) or hypertonic saline (7.5% NaCl, HS group) was administered through the tail vein (6 ml/kg). The CD4(+) and CD(8+), primarily T-lymphocytes subpopulation yielded from the intestinal tissues, were determined by immunohistochemistry.

Results

A pro-inflammatory cytokine, tumor necrosis factor (TNF)-α, and nuclear factor kappa B (NF-κB), a critical transcription factor for the TNF-α gene, were measured in the intestinal and lung tissues with ELISA. HS induced an increase in CD4(+) and CD8(+) T cells in the jejunum and ileum compared with the NS group. The levels of TNF-α and NF-κB in the intestinal and lung tissues were significantly decreased in the HS group compared with those of the NS group.

Conclusions

HS treatment may ameliorate the tissue damage induced by intestinal I/R. This protective effect is possibly due to its ability to activate the CD4(+) and CD8(+) T-lymphocytes cells in the intestinal tissues and inhibit the intestinal I/R-induced expression of pro-inflammatory cytokines.

Citations & impact 


Impact metrics

Jump to Citations

Citations of article over time

Article citations


Go to all (7) article citations

Similar Articles 


To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.


    • Get citation

    • Claim to ORCID